Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight management and diabetes treatment. Offering a dual-action mechanism targeting GLP-1 and GIP receptors,

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.

Obesity affects approximately 100 million Indian adults and is linked to over 200 health complications, including heart disease, hypertension, and sleep apnea. Recently, demand for GLP-1 drugs that promote weight loss has skyrocketed. The market could hit $100 billion by 2030, Goldman Sachs predicts.